Journal of Analytical Oncology最新文献

筛选
英文 中文
New Insights on Hyperbaric Oxygen Therapy for Cancer 高压氧疗法治疗癌症的新见解
Journal of Analytical Oncology Pub Date : 2024-06-12 DOI: 10.30683/1927-7229.2024.13.02
M. J. Gonzalez, J. Miranda-Massari, M. J. Gonzalez, J. Olalde, Miguel J. Berdiel, Liza Cardona
{"title":"New Insights on Hyperbaric Oxygen Therapy for Cancer","authors":"M. J. Gonzalez, J. Miranda-Massari, M. J. Gonzalez, J. Olalde, Miguel J. Berdiel, Liza Cardona","doi":"10.30683/1927-7229.2024.13.02","DOIUrl":"https://doi.org/10.30683/1927-7229.2024.13.02","url":null,"abstract":"Hypoxia is a critical characteristic of malignant tumors and involves enhanced cell survival, angiogenesis, glycolytic metabolism, and metastasis. Hyperbaric oxygen treatment (HBOT) has been used to improve and cure disorders involving hypoxia and ischemia, HBOT enhances the amount of dissolved oxygen in the plasma and thereby increasing O2 delivery to the tissue. Studies on HBOT and cancer have mostly focused on whether enhanced oxygen may act as a promoter of cancer. As oxygen is believed to be required for all the major processes of wound healing, including angiogenesis, this particular idea would give the impression that HBOT will promote cancer growth and recurrence. Nevertheless, this is not the case since the use of HBOT in patients with malignancies should be considered safe and therapeutic. There is no evidence indicating that HBO neither acts as a stimulator of tumor growth nor as an enhancer of recurrence. On the other hand, there is evidence that implies that HBO has tumor-inhibitory effects, this manuscript pretends to expand our knowledge on the effect and the mechanisms behind tumor oxygenation by HBOT.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141351780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemically Induced Brain Cancer in Sprague-Dawley Rats: Changed Lipidomics Mimics the Human Conditions 化学诱导的 Sprague-Dawley 大鼠脑癌:改变后的脂质组学模拟人类状况
Journal of Analytical Oncology Pub Date : 2024-04-22 DOI: 10.30683/1927-7229.2024.13.01
A. Leskanicova, P. Simko, M. Babinčák, A. Blicharova, M. Kertys, J. Kostolný, D. Maceková, T. Kiskova
{"title":"Chemically Induced Brain Cancer in Sprague-Dawley Rats: Changed Lipidomics Mimics the Human Conditions","authors":"A. Leskanicova, P. Simko, M. Babinčák, A. Blicharova, M. Kertys, J. Kostolný, D. Maceková, T. Kiskova","doi":"10.30683/1927-7229.2024.13.01","DOIUrl":"https://doi.org/10.30683/1927-7229.2024.13.01","url":null,"abstract":"Malignant gliomas are one of the most treatment-refractory cancers. Development of resistance to chemo- and radiotherapies contributes to these tumors’ aggressive phenotypes. Elevated lipid levels in gliomas have been reported for the last 50 years. However, the molecular mechanisms of how tumor tissues obtain lipids and utilize them are not well understood.In our study, 48.6% of phosphatidylcholines were significantly changed during an early stage of brain cancer in females, and 66.2% in males. As for lysophosphatidylcholines 57.1% metabolites were significantly changed in female, and 64.3% in male rats. We observed the most interesting results in the group of sphingomyelins, where 85.8% metabolites were significantly elevated during brain cancer. According to VIP projection, the most important metabolites were: PC ae C40:3, PC ae C38:1, PC ae C30:1, PC ae C38:3, PC ae C44:3, PC aa C40:2, PC aa C42:0, PC ae C30:2, SM C20:2, PC aa C42:1 in females, and PC ae C38:1, PC ae C40:3, PC ae C30:1, PC ae C42:1, SM C20:2, PC aa C34:4, PC ae C38:4, PC aa C32:2, PC aa C38:5, lysoPC a C14:0. The identification of lipid biomarkers during the early stage of cancer could improve patient prognosis.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140675301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple Primary Malignant Tumours 多发性原发性恶性肿瘤
Journal of Analytical Oncology Pub Date : 2023-12-11 DOI: 10.30683/1927-7229.2023.12.09
Sajad Ahmad Salati, Amjaad Alkhezzi, Mohammad Ahmed Elmuttalut, Muhammad Munir Memon, Mushhood Memon
{"title":"Multiple Primary Malignant Tumours","authors":"Sajad Ahmad Salati, Amjaad Alkhezzi, Mohammad Ahmed Elmuttalut, Muhammad Munir Memon, Mushhood Memon","doi":"10.30683/1927-7229.2023.12.09","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.09","url":null,"abstract":"Two or more histologically distinct malignancies in one individual are termed as multiple primary malignant tumours (MPMT). The incidence of these cases has been rising over the past few decades, primarily due to improved methods for cancer screening, diagnosis, treatment, and follow-up. They can show up as metachronous lesions later on or synchronously with the index malignancy. The precise aetiology is still unknown; however, a number of epidemiological variables have been proposed as potential risk factors. Modern imaging techniques are very helpful in the diagnosing process. Physician awareness is essential in order to raise suspicions about the potential for MPMT and to conduct appropriate investigations. There are currently no universal protocols based on evidence; instead, management is empirical and dependent on the judgments made by interdisciplinary teams.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138979439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Magnetotherapy in Experimental and Clinical Neuro-Oncology: A Review 磁疗在实验和临床神经肿瘤:综述
Journal of Analytical Oncology Pub Date : 2023-10-12 DOI: 10.30683/1927-7229.2023.12.08
F.F. Borichevsky, I.S. Lioubichtchev, A.E. Sahun, A.S. Trus, D.A. Tzerkovsky
{"title":"Magnetotherapy in Experimental and Clinical Neuro-Oncology: A Review","authors":"F.F. Borichevsky, I.S. Lioubichtchev, A.E. Sahun, A.S. Trus, D.A. Tzerkovsky","doi":"10.30683/1927-7229.2023.12.08","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.08","url":null,"abstract":"The purpose of this publication is not to state the fact of the high antitumor effectiveness of the gold standard treatment of malignant brain tumors (surgical intervention with adjuvant chemoradiotherapy), but to consider the possibility of using alternative therapeutic options, in particular, magnetotherapy, as a component of the treatment of patients with this serious pathology, as well as a method of preventing a number of postoperative adverse reactions.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136012605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Uterine Metastasis from Carcinoma of Breast – A Systematic Analysis 乳腺癌子宫转移的系统分析
Journal of Analytical Oncology Pub Date : 2023-07-10 DOI: 10.30683/1927-7229.2023.12.07
Sajad Ahmad Salati, Mohammed Alfehaid, Lamees AlSulaim, S. Alsuwaydani, M. Elmuttalut
{"title":"Uterine Metastasis from Carcinoma of Breast – A Systematic Analysis","authors":"Sajad Ahmad Salati, Mohammed Alfehaid, Lamees AlSulaim, S. Alsuwaydani, M. Elmuttalut","doi":"10.30683/1927-7229.2023.12.07","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.07","url":null,"abstract":"Breast cancer can metastasize to a wide range of organs, but reports about uterine metastases are rare. The current article systematically analyzes 55 patients reported in peer-reviewed literature from 2010–2022 with respect to nine variables, including: [i] age of the patient; [ii] clinical presentation of uterine metastasis; [iii] precise location of metastasis; [iv] primary (breast) cancer histopathology; [v] imaging modality utilized for detection of metastasis; [vi] timing of appearance of metastases: synchronous or metachronous; [vii] immunochemistry markers; [viii] management; and [ix] survival. Uterine metastases may appear in synchronous or metachronous fashion and may be asymptomatic or have symptoms like abnormal vaginal bleeding. Treatment of uterine metastases usually comprises of total abdominal hysterectomy with bilateral salpingo-oophorectomy along with chemotherapy. The long-term prognosis is unclear, but due to the development of metastases in other bodily parts, cases frequently have a poor outcome.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89642531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
True One Cell Chemical Analysis in Cancer Research: A Review 真单细胞化学分析在癌症研究中的应用综述
Journal of Analytical Oncology Pub Date : 2023-05-10 DOI: 10.30683/1927-7229.2023.12.06
Karen Reyes, G. Verbeck
{"title":"True One Cell Chemical Analysis in Cancer Research: A Review","authors":"Karen Reyes, G. Verbeck","doi":"10.30683/1927-7229.2023.12.06","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.06","url":null,"abstract":"True One Cell (TOC) analysis Is becoming highly critical for functional studies of cancer cells. This is partially because it is the only form of analysis that provides an avenue for studying the heterogeneity and cell-to-cell variations of individual cancer cells, thus providing unique insight into complex regulatory processes that govern TOC functions within a tumor. Additionally, true one cell techniques are playing an increasingly important role in current attempts to implement TOC metabolomic and proteomic studies, as well as emerging attempts to spatially resolve TOC information. In this review we provide a brief overview of the basis of the field and discuss its applications in TOC metabolomics and proteomics.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89741320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival Outcomes in High-Risk, Resected Colorectal Cancer with and without Maintenance Therapy 高风险、切除的结直肠癌患者接受和不接受维持治疗的生存结局
Journal of Analytical Oncology Pub Date : 2023-05-01 DOI: 10.30683/1927-7229.2023.12.05
M. Auber, S. Wen, Francesca Farran, G. Higa
{"title":"Survival Outcomes in High-Risk, Resected Colorectal Cancer with and without Maintenance Therapy","authors":"M. Auber, S. Wen, Francesca Farran, G. Higa","doi":"10.30683/1927-7229.2023.12.05","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.05","url":null,"abstract":"Introduction: Deaths due to colorectal cancer are disproportionately higher than either breast or prostate cancers even though the majority of new cases are potentially curable at diagnoses. If only half of the losses is due to metastatic disease at diagnosis, then a share of the remaining deaths must be attributable to tumor recurrence after presumptively curative therapy of early-stage disease. If so, current management of the latter group is suboptimal for a considerable number of subjects, a perception which argues for an assessment of maintenance therapy. Moreover, most recurrences occur within 24 months after standard surgical and (neo)adjuvant therapies. \u0000Objective: To assess relapse-free and overall survival among patients with high-risk, resected tumors who did and did not receive maintenance therapy following completion of treatment according to accepted guidelines. \u0000Methods: Pertinent clinical details were collected on 85 subjects, 37 who were, and 48 who were not, treated with maintenance therapy. Descriptive statistical analyses related to survival outcomes were performed on accumulated data. Wilcoxon rank test and Fisher’s exact test were used to examine the continuous and categorical variables, respectively. Kaplan-Meier method and log-rank test were used to analyze between-group relapse-free and overall survival. \u0000Results: Of the entire cohort, 63 of 85 (74.1%) subjects have no evidence of disease, a median of 5 years from the end of adjuvant therapy. Kaplan-Meier analyses indicated statistically, but not necessarily clinically, non-significant differences in median 5-year relapse-free survival, 79.8% vs 69.2%, and overall survival, 87.8% vs 81.7% in the treated and untreated groups of patients, respectively. A total of 21 subjects died; three of seven (treated group) and all 14 (untreated group) due to cancer. \u0000Conclusion: Obscured is the hint that maintenance therapy is clinically more effective than what the p-value intimates. The results of this retrospective data collection and analyses suggest that some patients with early-stage, high-risk disease, will derive survival benefits with maintenance therapy.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88920629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Photodynamic Therapy with Chlorine-Based Photosensitizer in the Treatment of Basal Cell Carcinomas 氯基光敏剂光动力疗法治疗基底细胞癌的疗效
Journal of Analytical Oncology Pub Date : 2023-04-03 DOI: 10.30683/1927-7229.2023.12.03
T. Artsemyeva, D. Tzerkovsky
{"title":"Efficacy of Photodynamic Therapy with Chlorine-Based Photosensitizer in the Treatment of Basal Cell Carcinomas","authors":"T. Artsemyeva, D. Tzerkovsky","doi":"10.30683/1927-7229.2023.12.03","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.03","url":null,"abstract":"The aim of this study is to evaluate a safety and antitumor efficacy of photodynamic therapy (PDT) with chlorine-based photosensitizer (PS) for treatment patients with basal cell skin carcinomas (BCC). \u0000Material and Methods: The work was performed on the basis of the Department of hyperthermia and photodynamic therapy. The object of the study were 172 patients with a verified diagnosis of BCC (T1N0M0, I stage), who received treatment from 2007 to 2022. PS «Photolon» (RUE «Belmedpreparaty», Republic of Belarus) was administrated intravenously at a dose of 2.0-2.5 mg/kg. The session of PDT was performed 2.5-3 h after intravenous injection of PS using semiconductor lasers (λ=660±5 nm) with exposure doses 50-250 J/cm² and power density – 0.15-0.5 W/cm². Frequency and severity of side effects after treatment session was assessed based on the criteria CTCAE (Version 4.03; 2010). The antitumor efficacy was evaluated 3 months after treatment. Clinical outcome was evaluated visually and morphologically by cytological or histopathological examination. Performance criteria were as follows (according to WHO, 1979). \u0000Results: The phenomenon of skin phototoxicity due to violation of the light regime (hyperemia, burning, slight swelling of the soft tissues of the face; CTCAE, I-II grades) was registered in 5.8% of cases (n=10). Serious adverse reactions (anaphylactic shock, Quincke's edema, severe pain syndrome) after the administration of PS and photoirradiation were not identified. Complete and partial regressions of tumors was observed in 93.0% and 4.7% of patients, respectively. The objective answer was 97.7%. The frequency of local relapses of the disease 1, 2, 3, 4 and 5 years after PDT was 3.1%, 3.1%, 4.6%, 4.6% and 6.9%, respectively. \u0000Сonclusion: PDT is a well-tolerated and highly effective therapeutic option in patients with BCC.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81976246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Virchow-Troisier's Node: A Review Virchow-Troisier's Node:综述
Journal of Analytical Oncology Pub Date : 2023-04-03 DOI: 10.30683/1927-7229.2023.12.04
Sajad Ahmad Salati, S. Alsuwaydani
{"title":"Virchow-Troisier's Node: A Review","authors":"Sajad Ahmad Salati, S. Alsuwaydani","doi":"10.30683/1927-7229.2023.12.04","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.04","url":null,"abstract":"Virchow-Troisier's node is an eponymous term referring to the enlargement of the left supraclavicular lymph node. It is a significant physical finding that generally indicates the late manifestation of a variety of malignancies. This review article briefly revisits the historical background, epidemiology, anatomical routes of metastasis, clinical presentation, differential diagnosis, and clinical significance of Virchow-Troisier's node.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76575795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sister Mary Joseph Nodule (SMJN) – A Review 玛丽·约瑟夫·诺杜勒修女(SMJN) -回顾
Journal of Analytical Oncology Pub Date : 2023-02-08 DOI: 10.30683/1927-7229.2023.12.02
Sajad Ahmad Salati, Lamees AlSulaim
{"title":"Sister Mary Joseph Nodule (SMJN) – A Review","authors":"Sajad Ahmad Salati, Lamees AlSulaim","doi":"10.30683/1927-7229.2023.12.02","DOIUrl":"https://doi.org/10.30683/1927-7229.2023.12.02","url":null,"abstract":"Sister Mary Joseph Nodule is an eponymous term referring to an umbilical nodule harbouring malignant metastatic cancer. It is a physical finding that is uncommon yet significant since it indicates the late manifestation of a variety of deep-seated abdominopelvic malignancies. This review article briefly revisits the historical background, epidemiology, anatomical routes of metastasis, clinical presentation, differential diagnosis, diagnostic work-up, clinical significance and prognosis of Sister Mary Joseph’s nodule.","PeriodicalId":14957,"journal":{"name":"Journal of Analytical Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74180162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信